TLRY - Weed Stocks Skyrocket Could There Be More Upside? Analyst Draws Scenarios | Benzinga
The Department of Health and Human Services (HHS) suggested the DEA reclassify cannabis as a Schedule III controlled substance under federal law. Assistant Secretary for Health Rachel Levine's letter triggered a much-needed rally in cannabis stocks.
In a recent analyst note, a leading cannabis equity research firm, Zuanic & Associates (Z&A), delved into potential scenarios, after the transcended events.
Seeking clarity, cannabis investors are invited to meet Pablo Zuanic, chief analyst at Z&A, at the Benzinga Cannabis Capital Conference in Chicago, September 27-28. Engage in conversations about the potential scenarios in the U.S. cannabis market and gain invaluable insights from a prominent industry analyst.
Options And Best-Case Scenarios
AdviserShares Pure US Cannabis ETF (ARCA: MSOS) and the ETFMG Alternative Harvest ETF (ARCA: MJUS) surged, accompanied by prominent companies such as Canopy Growth Corporation (NASDAQ: CGC), Curaleaf Holdings, Inc. (OTC: CURLF), Tilray, Inc. (NASDAQ: TLRY), Cresco Labs, Inc. (OTC: CRLBF), Green Thumb Industries Inc. (OTC: GTBIF), and Trulieve Cannabis Corp. (OTC: TCNNF).
Pablo Zuanic, Z&A's chief analyst, outlines three plausible scenarios for the future of the cannabis market in light of the HHS's reclassification recommendation.
These scenarios encompass moving medical cannabis to Schedule III, potentially enabling it to be federally approved as a pharmaceutical product, while maintaining ...